Durlobactam is a beta-lactamase inhibitor used in combination with sulbactam to treat susceptible strains of bacteria in the genus Acinetobacter[1] It is an analog of avibactam.
The combination therapy sulbactam/durlobactam was approved for medical use in the United States in May 2023.[1]
See also
References
- ^ a b “FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria”. U.S. Food and Drug Administration (Press release). 24 May 2023. Retrieved 24 May 2023.[dead link]
This article incorporates text from this source, which is in the public domain.
Further reading
- Shapiro AB, Moussa SH, McLeod SM, Durand-Réville T, Miller AA (2021). “Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam”. Frontiers in Microbiology. 12 709974. doi:10.3389/fmicb.2021.709974. PMC 8328114. PMID 34349751.
- Papp-Wallace KM, McLeod SM, Miller AA (May 2023). “Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species”. Clinical Infectious Diseases. 76 (Supplement_2): S194–S201. doi:10.1093/cid/ciad095. PMC 10150275. PMID 37125470.
